These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 18707801

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 5. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N, Martín AB, Mendialdua A, Moratalla R.
    Biol Psychiatry; 2006 Jan 01; 59(1):64-74. PubMed ID: 16139809
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL, Gupta V, Alam S, Park JY, Bishop C.
    Pharmacol Biochem Behav; 2007 Jan 01; 87(3):306-14. PubMed ID: 17553556
    [Abstract] [Full Text] [Related]

  • 10. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.
    Neuropharmacology; 2015 Jun 01; 93():52-67. PubMed ID: 25645393
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhao R, Lu W, Fang X, Guo L, Yang Z, Ye N, Zhao J, Liu Z, Jia J, Zheng L, Zhao B, Zhang A, Zhen X.
    Pharmacol Biochem Behav; 2014 Sep 01; 124():204-10. PubMed ID: 24955866
    [Abstract] [Full Text] [Related]

  • 13. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C, Crossman AR, Ravenscroft P.
    Exp Neurol; 2013 Sep 01; 247():476-84. PubMed ID: 23360800
    [Abstract] [Full Text] [Related]

  • 14. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
    Dupre KB, Eskow KL, Negron G, Bishop C.
    Brain Res; 2007 Jul 16; 1158():135-43. PubMed ID: 17553470
    [Abstract] [Full Text] [Related]

  • 15. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F, Millan MJ, Brocco M, Morari M.
    Neuropharmacology; 2010 Feb 16; 58(2):528-36. PubMed ID: 19733554
    [Abstract] [Full Text] [Related]

  • 16. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M.
    Neurosci Res; 2005 Jun 16; 52(2):185-94. PubMed ID: 15893579
    [Abstract] [Full Text] [Related]

  • 17. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.
    Brain Res Bull; 2004 Aug 30; 64(2):155-64. PubMed ID: 15342103
    [Abstract] [Full Text] [Related]

  • 18. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
    Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD.
    Eur J Neurosci; 2006 May 30; 23(10):2669-76. PubMed ID: 16817869
    [Abstract] [Full Text] [Related]

  • 19. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R.
    Biol Psychiatry; 2009 Sep 15; 66(6):603-13. PubMed ID: 19520364
    [Abstract] [Full Text] [Related]

  • 20. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK, Martin-Negrier ML, Bezard E, Crossman AR, Ravenscroft P.
    Neurobiol Dis; 2014 Oct 15; 70():138-48. PubMed ID: 24969021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.